European Journal of Clinical Pharmacology

Papers
(The H4-Index of European Journal of Clinical Pharmacology is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Might chronic spontaneous urticaria develop after SARS-CoV-2 vaccinations?174
Oral Melatonin for Pain Relief During Venepuncture in Neonates– a Pilot Randomized Control Trial83
How to make the best of NLRP3 inhibitors in patients with COVID-19?73
A Study Of the effect of Sex on drug dosing, concentrations, and pharmacogenomics in the Montreal Heart Institute Hospital Cohort (SOS-PGx): methodology and research progress57
Correction to: A real-world pharmacovigilance study of adverse events associated with esketamine: disproportionality analysis and detection of potential drug-drug interaction signals44
Identification of novel signal of DRESS associated with antibiotics: a disproportionality analysis of the FDA adverse event reporting system (FAERS) database41
Lowering cyclosporine trough concentration threshold effectively mitigates acute graft-versus-host disease in children with severe β-Thalassemia post hematopoietic stem cell transplantation40
A systematic literature review of economic evaluations of setmelanotide37
Use of overactive bladder anticholinergic medications associated with falls leading to emergency department visits: results from the ADRED study34
Population pharmacokinetics and pharmacodynamics of meropenem in critically ill patients with renal impairment or on continuous renal replacement therapy34
The Effect of the combination therapy of statin and dapagliflozin, a selective inhibitor of sodium_glucose Co-transporter type 2, in the treatment of Ischemic heart disease with heart failure: A rando33
Signal detection between 5-alpha reductase inhibitors and the risk of suicidality and depression: an international pharmacovigilance analysis33
A phase 1 study in healthy participants to characterize the safety and pharmacology of inclacumab, a fully human anti-P-selectin antibody, in development for treatment of sickle cell disease33
Understanding attitudes towards psychiatric medications: a comparative study of patients, healthcare professionals, and general population perspectives30
Incidence and risk factors of drug-induced kidney injury in children: a systematic review and meta-analysis29
Beyond safety: adverse events and unanticipated advantages of SGLT2 inhibitors29
Effects of sodium-glucose cotransporter 2 inhibitors on renal risk factors in patients with abnormal glucose metabolism: a meta-analysis of randomized controlled trials27
Usefulness of mirtazapine and SSRIs in late-life depression: post hoc analysis of the GUNDAM study27
The efficacy and safety of direct oral anticoagulants versus vitamin K antagonists in patients with left-sided bioprosthetic heart valves and atrial fibrillation: a systematic review and meta-analysis26
Assessment of body mass-related covariates for rifampicin pharmacokinetics in healthy Caucasian volunteers25
Comment on “Use of statins and risks of ovarian, uterine, and cervical diseases: a cohort study in the UK Biobank”25
Relationship between CYP2C8, UGT1A1, and ABCG2 gene polymorphisms and the exposure, efficacy, and toxicity of eltrombopag in the treatment of refractory aplastic anemia24
Economic evaluation of antibody-drug conjugates (ADCs) in patients with breast cancer: systematic review24
0.23309206962585